Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST).

Tsuyoshi Takahashi,Toshirou Nishida,Toshihiro Kudo,Narikazu Boku,Yoshitaka Honma,Yoshito Komatsu,Hiroshi Nakatsumi,Koji Matsumoto,Takuma Onoe,Eiji Oki,Masako Nakamoto,Miki Fukutani,Shogo Nomura,Akihiro Sato,Yoichi Naito,Toshihiko Doi

Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST).

2020

Tsuyoshi Takahashi
Toshirou Nishida
Toshihiro Kudo
Narikazu Boku
Yoshitaka Honma
Yoshito Komatsu
Hiroshi Nakatsumi
Koji Matsumoto
Takuma Onoe
Eiji Oki
Masako Nakamoto
Miki Fukutani
Shogo Nomura
Akihiro Sato
Yoichi Naito
Toshihiko Doi

823Background: Imatinib is a standard first line treatment for advanced gastrointestinal stromal tumor (GIST); however eventually almost all the GISTs become resistant to imatinib. Secondary mutati...

Keywords:

Second-line therapy
Regorafenib
Stromal tumor
Internal medicine
Medicine
Imatinib
Oncology
GiST
Pathology
imatinib resistant
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations